Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
InSightec
National Institutes of Health Clinical Center (CC)
ImmunityBio, Inc.
Technische Universität Dresden
Boehringer Ingelheim
AbbVie
Norwegian University of Science and Technology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RayzeBio, Inc.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Henry Ford Health System
MediLink Therapeutics (Suzhou) Co., Ltd.
Big Ten Cancer Research Consortium
Boehringer Ingelheim
Pfizer
KaliVir Immunotherapeutics
Alliance for Clinical Trials in Oncology
Hoffmann-La Roche
Genentech, Inc.
Hoffmann-La Roche
Zai Lab (Hong Kong), Ltd.
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim
Hoffmann-La Roche
Imugene Limited
The Methodist Hospital Research Institute
Gustave Roussy, Cancer Campus, Grand Paris